0001415889-24-010433.txt : 20240405
0001415889-24-010433.hdr.sgml : 20240405
20240405165541
ACCESSION NUMBER: 0001415889-24-010433
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240403
FILED AS OF DATE: 20240405
DATE AS OF CHANGE: 20240405
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Farzan Nima
CENTRAL INDEX KEY: 0001808296
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39743
FILM NUMBER: 24827214
MAIL ADDRESS:
STREET 1: C/O KEROS THERAPEUTICS, INC.
STREET 2: 99 HAYDEN AVENUE, SUITE 120, BUILDING E
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kinnate Biopharma Inc.
CENTRAL INDEX KEY: 0001797768
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 824566526
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11975 EL CAMINO REAL, STE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 8582994699
MAIL ADDRESS:
STREET 1: 11975 EL CAMINO REAL, STE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
form4-04052024_040430.xml
X0508
4
2024-04-03
1
0001797768
Kinnate Biopharma Inc.
KNTE
0001808296
Farzan Nima
800 WEST EL CAMINO REAL
SUITE 180
MOUNTAIN VIEW
CA
94040
true
true
false
false
CHIEF EXECUTIVE OFFICER
0
Common Stock
2024-04-03
4
D
0
2186
D
0
D
Stock Option (right to buy)
2.57
2024-04-03
4
D
0
1281642
D
2030-03-23
Common Stock
1281642
0
D
Stock Option (right to buy)
5.63
2024-04-03
4
D
0
437413
D
2030-08-18
Common Stock
437413
0
D
Stock Option (right to buy)
35.38
2024-04-03
4
D
0
275000
D
2031-02-12
Common Stock
275000
0
D
Stock Option (right to buy)
10.03
2024-04-03
4
D
0
400000
D
2032-02-11
Common Stock
400000
0
D
Stock Option (right to buy)
6.78
2024-04-03
4
D
0
750000
D
2033-02-10
Common Stock
750000
0
D
Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR.
This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the per share exercise price of such in-the-money option by (y) the number of shares underlying such in-the-money option, plus (ii) one CVR for each share underlying such in-the-money option.
This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
/s/ James P. Reilly, Attorney-in-Fact
2024-04-05